LXE408

DRUG4 trials

Sponsors

Drugs for Neglected Diseases, Novartis Pharmaceuticals

Conditions

Chagas DiseaseLocalized Cutaneous LeishmaniasisPrimary Visceral Leishmaniasis

Phase 2

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Active, not recruitingNCT05593666

Drugs for Neglected DiseasesPrimary Visceral Leishmaniasis

Start: 2022-12-27End: 2025-12-30Updated: 2025-12-18

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

CompletedNCT05957978

Drugs for Neglected DiseasesPrimary Visceral Leishmaniasis

Start: 2024-03-29End: 2025-11-13Updated: 2025-12-18

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

RecruitingNCT06632600

Novartis PharmaceuticalsChagas Disease

Start: 2025-04-28End: 2030-09-21Target: 130Updated: 2026-03-30

A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

Not yet recruitingNCT06997159

Drugs for Neglected DiseasesLocalized Cutaneous Leishmaniasis

Start: 2025-11-16End: 2027-07-10Target: 250Updated: 2025-05-30